Advances in the Long-Term Treatment of Obesity

2004 ◽  
Vol 12 (S12) ◽  
pp. 149S-150S ◽  
Author(s):  
Samuel Klein
Keyword(s):  
Term Treatment ◽  
Long Term Treatment ◽  
Treatment Of Obesity

Orlistat in the Long-term Treatment of Obesity in Primary Care Settings.

2001 ◽  
Vol 21 (1) ◽  
pp. 53
Author(s):  
J Hauptman ◽  
C Lucas ◽  
M N Boldrin ◽  
H Collins ◽  
K R Segal
Keyword(s):  
Primary Care ◽  
Term Treatment ◽  
Primary Care Settings ◽  
Long Term Treatment ◽  
Treatment Of Obesity

Short-Term and Long-Term Clinical Evaluation of a Non-Amphetaminic Anorexiant (Mazindol) in the Treatment of Obesity

1976 ◽  
Vol 4 (5) ◽  
pp. 305-318 ◽  
Author(s):  
G Enzi ◽  
A Baritussio ◽  
E Marchiori ◽  
G Crepaldi
Keyword(s):  
Clinical Trial ◽  
Weight Loss ◽  
Crossover Trial ◽  
Late Phase ◽  
Term Treatment ◽  
Short Term ◽  
Long Term Treatment ◽  
Simple Obesity ◽  
Treatment Of Obesity

The effectiveness and tolerance of a non-amphetaminic anorexiant drug has been evaluated in a short-term and in a long-term clinical trial in simple obesity and in refractory obesity. In the short-term ‘crossover’ trial, a more evident effectiveness and tolerance result when the anorexiant is given in a late phase of treatment. The association of an anorexiant drug with the hypocaloric diet was seen to be effective in the treatment of so-called refractory obesity. In the evaluation of the long-term treatment it is seen that weight loss is greater and remains so for longer periods in patients receiving anorexiant, as compared to controls. This is related to a better maintenance of a restricted calorie regimen. Mazindol did not affect the improvement of glucose tolerance and insulin secretion which follows the weight reduction.

scholarly journals Observations on obese patients eating isocaloric reducing diets with varying proportions of carbohydrate

1970 ◽  
Vol 24 (1) ◽  
pp. 39-44 ◽  
Author(s):  
Cathryn E. A. Hood ◽  
J. M. Goodhart ◽  
R. F. Fletcher ◽  
Josephine Gloster ◽  
P. V. Bertrand ◽  
...  
Keyword(s):  
Weight Loss ◽  
Term Treatment ◽  
Obese Patients ◽  
Long Term Treatment ◽  
Significant Difference ◽  
Simple Obesity ◽  
Treatment Of Obesity ◽  
Sparing Effect

1. Diets containing 1000 kcal/day with varying proportions of carbohydrate (CHO) were fed to four women with simple obesity. The patients were given, in various sequences and for 8 days in each instance, diets in which 3, 6, 12, 25 or 50% of the calories were supplied by sucrose.2. No significant difference in the rate of weight loss was found when the diets of graded CHO content were fed and mean weight loss was 1.2 kg/week.3. The high-CHO diets were antiketogenic; there was no daily relationship between urinary ketones and sodium. The 25 and 50% CHO diets had a nitrogen-sparing effect.4. A 1000 kcal/day diet with about a third of the calories derived from CHO leads to a useful rate of weight loss and minimum changes in body chemistry. This finding may have implications in the long-term treatment of obesity.

2050-P: A Multifactorial Telemedical Care Model for Long-Term Treatment of Obesity—A Randomized Controlled Trial

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2050-P
Author(s):  
RÖHLING MARTIN ◽  
KATHARINA MARTIN ◽  
SABINE ELLINGER ◽  
STEPHAN MARTIN ◽  
KERSTIN KEMPF
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Term Treatment ◽  
Care Model ◽  
Randomized Controlled ◽  
Long Term Treatment ◽  
Treatment Of Obesity ◽  
Telemedical Care

scholarly journals Present and Future: Pharmacologic Treatment of Obesity

2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Mariela Glandt ◽  
Itamar Raz
Keyword(s):  
Side Effects ◽  
Cardiovascular Events ◽  
Term Treatment ◽  
Pharmacologic Treatment ◽  
Increased Risk ◽  
Long Term Treatment ◽  
Diet And Exercise ◽  
Prevention And Treatment ◽  
Treatment Of Obesity

Obesity now presents one of the biggest health problems of our times. Diet and exercise are best for both prevention and treatment; unfortunately, both require much discipline and are difficult to maintain. Medications offer a possible adjunct, but their effect is modest, they are limited by side effects, and the weight loss lasts only as long as the drug is being taken, since as soon as treatment is stopped, the weight is regained. Sibutramine, a sympathomimetic medication which was available for long-term treatment, is the most recent of the drugs to be withdrawn from the market due to side effects; in this case it was an increased risk of cardiovascular events. This paper reviews those medications which are available for treatment of obesity, including many of those recently taken off the market. It also discusses some of the newer treatments that are currently being investigated.

scholarly journals Effective long-term treatment of obesity: a continuing care model

2000 ◽  
Vol 24 (7) ◽  
pp. 893-898 ◽  
Author(s):  
JD Latner ◽  
AJ Stunkard ◽  
GT Wilson ◽  
ML Jackson ◽  
DS Zelitch ◽  
...  
Keyword(s):  
Term Treatment ◽  
Continuing Care ◽  
Care Model ◽  
Long Term Treatment ◽  
Treatment Of Obesity
Sign in / Sign up

Export Citation Format

Share Document